港股生物科技公司百奥赛图-B（02315）今日盘中大涨5.82%，引发市场广泛关注。该公司近期发布的2024年度业绩报告显示，公司实现了扭亏为盈，这一亮眼表现成为推动股价上涨的主要因素。
根据公告，百奥赛图2024年实现营收9.8亿元，同比增长36.8%；净利润3354万元，相比去年同期的亏损3.83亿元实现扭亏为盈。值得注意的是，公司的抗体发现业务表现出色，收入达到3.18亿元，同比大幅增长80.7%。此外，经营活动产生的现金流净额为2.11亿元，较去年的负7665万元显著改善，表明公司财务状况持续向好。
除了业绩改善，百奥赛图在人工智能（AI）技术与生物科技结合方面的进展也引发了投资者的关注。公司已完成AI驱动抗体药物研发平台DeepSeek的本地化部署，并将其与核心业务"千鼠万抗"计划全面协同，这一举措有望进一步提升公司在新药研发领域的竞争力。在生物科技行业整体复苏的背景下，百奥赛图的这一系列积极变化无疑增强了市场对其未来发展前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.